In this connection, [111In]In-labeled capromab pentapeptide (7E11-C5 antibody), known with the tread-mark of ProstaScintTM, was the first PSMA targeting tracer approved by Food Drug Administration in 1997 with the indication for use in PCa patients. This evidence concerns the gene FOLH1 and posterior cortical atrophy.